BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jacobs J, Smits E, Lardon F, Pauwels P, Deschoolmeester V. Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect. J Immunol Res 2015;2015:158038. [PMID: 26605342 DOI: 10.1155/2015/158038] [Cited by in Crossref: 40] [Cited by in F6Publishing: 44] [Article Influence: 5.7] [Reference Citation Analysis]
Number Citing Articles
1 Guo X, Huang M, Zhang H, Chen Q, Hu Y, Meng Y, Wu C, Tu C, Liu Y, Li A, Li Q, Zhou P, Liu S. A pan-cancer analysis of thioredoxin-interacting protein as an immunological and prognostic biomarker. Cancer Cell Int 2022;22. [DOI: 10.1186/s12935-022-02639-2] [Reference Citation Analysis]
2 Talaat IM, Elemam NM, Zaher S, Saber-ayad M. Checkpoint molecules on infiltrating immune cells in colorectal tumor microenvironment. Front Med 2022;9. [DOI: 10.3389/fmed.2022.955599] [Reference Citation Analysis]
3 Xiao J, Wang X, Liu Y, Liu X, Yi J, Hu J. Lactate Metabolism-Associated lncRNA Pairs: A Prognostic Signature to Reveal the Immunological Landscape and Mediate Therapeutic Response in Patients With Colon Adenocarcinoma. Front Immunol 2022;13:881359. [DOI: 10.3389/fimmu.2022.881359] [Reference Citation Analysis]
4 Chen Y, Zhang Y, Lu J, Liu Z, Zhao S, Zhang M, Lu M, Xu W, Sun F, Wu Q, Zhong Q, Cui Z. Characteristics of Prognostic Programmed Cell Death-Related Long Noncoding RNAs Associated With Immune Infiltration and Therapeutic Responses to Colon Cancer. Front Immunol 2022;13:828243. [PMID: 35711417 DOI: 10.3389/fimmu.2022.828243] [Reference Citation Analysis]
5 Ramírez-rico G, Drago-serrano ME, León-sicairos N, de la Garza M. Lactoferrin: A Nutraceutical with Activity against Colorectal Cancer. Front Pharmacol 2022;13:855852. [DOI: 10.3389/fphar.2022.855852] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
6 Raman P, Botrus G, Bekaii-saab T. Immunotherapy in the Treatment of Advanced Colorectal Cancer. Cancer Immunotherapy 2022. [DOI: 10.1007/13905_2021_12] [Reference Citation Analysis]
7 Daghestani MH, Ambreen K, Hakami HH, Omair MA, Saleem AM, Aleisa NA, AlNeghery LM, Amin MH, Alobaid HM, Omair MA, Hassen LM. Venom of the desert black snake Walterinnesia aegyptia enhances anti-tumor immunity via its beneficial modulatory effects on pro- and anti-tumorigenic inflammatory mediators in cultured colon cancer cells. Toxicol Res (Camb) 2021;10:1116-28. [PMID: 34956615 DOI: 10.1093/toxres/tfab093] [Reference Citation Analysis]
8 Zhang F, Qiao S. Research Progress on the Relationship Between Inflammation and Colorectal Cancer. Ann Gastroenterol Surg. [DOI: 10.1002/ags3.12517] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Chen S, Wang Y, Wang B, Zhang L, Su Y, Xu M, Zhang M. A signature based on 11 autophagy genes for prognosis prediction of colorectal cancer. PLoS One 2021;16:e0258741. [PMID: 34699544 DOI: 10.1371/journal.pone.0258741] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
10 Zhang P, Liu G, Lu L. N6-Methylandenosine-Related lncRNA Signature Is a Novel Biomarkers of Prognosis and Immune Response in Colon Adenocarcinoma Patients. Front Cell Dev Biol 2021;9:703629. [PMID: 34336856 DOI: 10.3389/fcell.2021.703629] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
11 Gomar M, Najafi M, Aghili M, Cozzi S, Jahanbakhshi A. Durable complete response to pembrolizumab in microsatellite stable colorectal cancer. Daru 2021. [PMID: 34254265 DOI: 10.1007/s40199-021-00404-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Amodio V, Mauri G, Reilly NM, Sartore-Bianchi A, Siena S, Bardelli A, Germano G. Mechanisms of Immune Escape and Resistance to Checkpoint Inhibitor Therapies in Mismatch Repair Deficient Metastatic Colorectal Cancers. Cancers (Basel) 2021;13:2638. [PMID: 34072037 DOI: 10.3390/cancers13112638] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 11.0] [Reference Citation Analysis]
13 Derakhshani A, Hashemzadeh S, Asadzadeh Z, Shadbad MA, Rasibonab F, Safarpour H, Jafarlou V, Solimando AG, Racanelli V, Singh PK, Najafi S, Javadrashid D, Brunetti O, Silvestris N, Baradaran B. Cytotoxic T-Lymphocyte Antigen-4 in Colorectal Cancer: Another Therapeutic Side of Capecitabine. Cancers (Basel) 2021;13:2414. [PMID: 34067631 DOI: 10.3390/cancers13102414] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 30.0] [Reference Citation Analysis]
14 Siozopoulou V, Domen A, Zwaenepoel K, Van Beeck A, Smits E, Pauwels P, Marcq E. Immune Checkpoint Inhibitory Therapy in Sarcomas: Is There Light at the End of the Tunnel? Cancers (Basel) 2021;13:360. [PMID: 33478080 DOI: 10.3390/cancers13020360] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 13.0] [Reference Citation Analysis]
15 Toor SM, Sasidharan Nair V, Murshed K, Abu Nada M, Elkord E. Tumor-Infiltrating Lymphoid Cells in Colorectal Cancer Patients with Varying Disease Stages and Microsatellite Instability-High/Stable Tumors. Vaccines (Basel) 2021;9:64. [PMID: 33477864 DOI: 10.3390/vaccines9010064] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
16 Kapoor S, Padwad YS. Immune Checkpoint Inhibitors as an Armor for Targeted Immunotherapy of Colorectal Cancer. Colon Cancer Diagnosis and Therapy 2021. [DOI: 10.1007/978-3-030-63369-1_15] [Reference Citation Analysis]
17 Chulkina M, Beswick EJ, Pinchuk IV. Role of PD-L1 in Gut Mucosa Tolerance and Chronic Inflammation. Int J Mol Sci 2020;21:E9165. [PMID: 33271941 DOI: 10.3390/ijms21239165] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
18 Yu X, Zhu L, Liu J, Xie M, Chen J, Li J. Emerging Role of Immunotherapy for Colorectal Cancer with Liver Metastasis. Onco Targets Ther 2020;13:11645-58. [PMID: 33223838 DOI: 10.2147/OTT.S271955] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
19 Daghestani MH, H. Hakami H, Ambreen K, Saleem AM, Aleisa NA, Al Neghery LM, Amin MH. Assessment of tumor-suppressive inflammatory tendency of Echis coloratus venom against colon carcinogenesis, via up-regulation of anti-tumorigenic inflammatory cells and down-regulation of pro-tumorigenic inflammatory cells, in colon cancer cell lines. Toxin Reviews. [DOI: 10.1080/15569543.2020.1818107] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Shakerin P, Sedighi Moghadam B, Baghaei K, Safaei Naraghi Z, Kamyab Hesari K, Asadzadeh Aghdaei H, Shokouhi Shoormasti R, Fazeli MS, Nourizadeh M. Increasing the expression of programmed death ligand 2 (PD-L2) but not 4-1BB ligand in colorectal cancer cells. Mol Biol Rep 2020;47:5689-97. [PMID: 32661872 DOI: 10.1007/s11033-020-05289-7] [Reference Citation Analysis]
21 Lima PMA, Torres LC, Martins MR, da Matta MC, Lima JTO, de Mello MJG, da Silva LM, Cintra EB Jr, Lira CCR, da Fonte EJA, Forones NM. Soluble levels of sCD40L and s4-1BB are associated with a poor prognosis in elderly patients with colorectal cancer. J Surg Oncol 2020;121:901-5. [PMID: 31858621 DOI: 10.1002/jso.25813] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
22 Matos AI, Carreira B, Peres C, Moura LI, Conniot J, Fourniols T, Scomparin A, Martínez-barriocanal Á, Arango D, Conde JP, Préat V, Satchi-fainaro R, Florindo HF. Nanotechnology is an important strategy for combinational innovative chemo-immunotherapies against colorectal cancer. Journal of Controlled Release 2019;307:108-38. [DOI: 10.1016/j.jconrel.2019.06.017] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 9.3] [Reference Citation Analysis]
23 Kong JC, Guerra GR, Pham T, Mitchell C, Lynch AC, Warrier SK, Ramsay RG, Heriot AG. Prognostic Impact of Tumor-Infiltrating Lymphocytes in Primary and Metastatic Colorectal Cancer: A Systematic Review and Meta-analysis. Dis Colon Rectum 2019;62:498-508. [PMID: 30844974 DOI: 10.1097/DCR.0000000000001332] [Cited by in Crossref: 34] [Cited by in F6Publishing: 40] [Article Influence: 11.3] [Reference Citation Analysis]
24 Tryakin AA, Khakimova GG, Zabotina TN, Borunova AA, Malikhova OA. Modern views on immunological biomarkers of colon cancer. Zlokač opuholi 2019;8:50-58. [DOI: 10.18027/2224-5057-2018-8-4-50-58] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
25 Callata-carhuapoma HR, García-foncillas López J. Immunological Treatment in Gastrointestinal Cancers. Textbook of Gastrointestinal Oncology 2019. [DOI: 10.1007/978-3-030-18890-0_26] [Reference Citation Analysis]
26 Alekseenko IV, Monastyrskaya GS, Sverdlov ED. Emerging Potential of Cancer Therapy—Binary Direct Interactions of Cancer and Stromal Cells. Russ J Genet 2018;54:1416-28. [DOI: 10.1134/s1022795418120025] [Reference Citation Analysis]
27 Koh B, Jeon H, Kim D, Kang D, Kim KR. Effect of fibroblast co-culture on the proliferation, viability and drug response of colon cancer cells. Oncol Lett 2019;17:2409-17. [PMID: 30675306 DOI: 10.3892/ol.2018.9836] [Cited by in Crossref: 13] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
28 Elashi AA, Sasidharan Nair V, Taha RZ, Shaath H, Elkord E. DNA methylation of immune checkpoints in the peripheral blood of breast and colorectal cancer patients. Oncoimmunology 2019;8:e1542918. [PMID: 30713804 DOI: 10.1080/2162402X.2018.1542918] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 8.0] [Reference Citation Analysis]
29 Jesus VHF, Felismino TC, Barros E Silva MJ, Souza E Silva V, Riechelmann RP. Current approaches to immunotherapy in noncolorectal gastrointestinal malignancies. Clinics (Sao Paulo) 2018;73:e510s. [PMID: 30365605 DOI: 10.6061/clinics/2018/e510s] [Reference Citation Analysis]
30 Sverdlov E. Missed Druggable Cancer Hallmark: Cancer-Stroma Symbiotic Crosstalk as Paradigm and Hypothesis for Cancer Therapy. BioEssays 2018;40:1800079. [DOI: 10.1002/bies.201800079] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
31 Alekseenko IV, Pleshkan VV, Sverdlov ED. Cancer–stroma interactions as a target for cancer treatment. Biopolym Cell 2018;34:271-283. [DOI: 10.7124/bc.000980] [Reference Citation Analysis]
32 Oronsky B, Larson C, Reid TR, Carter CA. Case Series: Abscopal Benefit of Surgery in 3 Immunotherapy-Treated Patients With Unresectable Cancer. J Investig Med High Impact Case Rep 2018;6:2324709618786319. [PMID: 30083560 DOI: 10.1177/2324709618786319] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
33 Veenstra CM, Krauss JC. Emerging Systemic Therapies for Colorectal Cancer. Clin Colon Rectal Surg 2018;31:179-91. [PMID: 29720904 DOI: 10.1055/s-0037-1602238] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
34 Jacobs J, Deschoolmeester V, Zwaenepoel K, Flieswasser T, Deben C, Van den Bossche J, Hermans C, Rolfo C, Peeters M, De Wever O, Lardon F, Siozopoulou V, Smits E, Pauwels P. Unveiling a CD70-positive subset of cancer-associated fibroblasts marked by pro-migratory activity and thriving regulatory T cell accumulation. Oncoimmunology 2018;7:e1440167. [PMID: 29900042 DOI: 10.1080/2162402X.2018.1440167] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
35 Li Y, Du Y, Liang X, Sun T, Xue H, Tian J, Jin Z. EGFR-targeted liposomal nanohybrid cerasomes: theranostic function and immune checkpoint inhibition in a mouse model of colorectal cancer. Nanoscale 2018;10:16738-49. [DOI: 10.1039/c8nr05803b] [Cited by in Crossref: 43] [Cited by in F6Publishing: 47] [Article Influence: 10.8] [Reference Citation Analysis]
36 Sorscher S, Resnick J, Goodman M. First Case Report of a Dramatic Radiographic Response to a Checkpoint Inhibitor in a Patient With Proficient Mismatch Repair Gene Expressing Metastatic Colorectal Cancer. JCO Precision Oncology 2017. [DOI: 10.1200/po.16.00005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
37 Sun X, Liu S, Wang D, Zhang Y, Li W, Guo Y, Zhang H, Suo J. Colorectal cancer cells suppress CD4+ T cells immunity through canonical Wnt signaling. Oncotarget 2017;8:15168-81. [PMID: 28147310 DOI: 10.18632/oncotarget.14834] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 5.4] [Reference Citation Analysis]
38 Rangel-Sosa MM, Aguilar-Córdova E, Rojas-Martínez A. Immunotherapy and gene therapy as novel treatments for cancer. Colomb Med (Cali) 2017;48:138-47. [PMID: 29213157 DOI: 10.25100/cm.v48i3.2997] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
39 De Simone M, Arrigoni A, Rossetti G, Gruarin P, Ranzani V, Politano C, Bonnal RJP, Provasi E, Sarnicola ML, Panzeri I, Moro M, Crosti M, Mazzara S, Vaira V, Bosari S, Palleschi A, Santambrogio L, Bovo G, Zucchini N, Totis M, Gianotti L, Cesana G, Perego RA, Maroni N, Pisani Ceretti A, Opocher E, De Francesco R, Geginat J, Stunnenberg HG, Abrignani S, Pagani M. Transcriptional Landscape of Human Tissue Lymphocytes Unveils Uniqueness of Tumor-Infiltrating T Regulatory Cells. Immunity. 2016;45:1135-1147. [PMID: 27851914 DOI: 10.1016/j.immuni.2016.10.021] [Cited by in Crossref: 369] [Cited by in F6Publishing: 298] [Article Influence: 73.8] [Reference Citation Analysis]
40 Chang YT, Yeh YS, Ma CJ, Huang CW, Tsai HL, Huang MY, Cheng TL, Wang JY. Optimization of a multigene biochip for detection of relapsed and early relapsed colorectal cancer. J Surg Res 2017;220:427-37. [PMID: 28711367 DOI: 10.1016/j.jss.2017.06.030] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
41 Bilgin B, Sendur MA, Bülent Akıncı M, Şener Dede D, Yalçın B. Targeting the PD-1 pathway: a new hope for gastrointestinal cancers. Curr Med Res Opin 2017;33:749-59. [PMID: 28055269 DOI: 10.1080/03007995.2017.1279132] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 9.2] [Reference Citation Analysis]
42 Şendur MAN, Aksoy S. Targeted Therapies and Immunotherapy in Bladder Cancer. Principles and Practice of Urooncology 2017. [DOI: 10.1007/978-3-319-56114-1_6] [Reference Citation Analysis]
43 Kulkarni A, Carley H. Advances in the recognition and management of hereditary cancer. Br Med Bull 2016;120:123-38. [PMID: 27941041 DOI: 10.1093/bmb/ldw046] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
44 de Vries NL, Swets M, Vahrmeijer AL, Hokland M, Kuppen PJ. The Immunogenicity of Colorectal Cancer in Relation to Tumor Development and Treatment. Int J Mol Sci 2016;17:E1030. [PMID: 27367680 DOI: 10.3390/ijms17071030] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 4.2] [Reference Citation Analysis]